IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms (2016)
- Authors:
- Autor USP: TRAINA, FABÍOLA - FMRP
- Unidade: FMRP
- DOI: 10.18632/oncotarget.6851
- Subjects: REAÇÃO EM CADEIA POR POLIMERASE; APOPTOSE; MUTAÇÃO GENÉTICA; LEUCEMIA
- Keywords: STAT5; Myeloproliferative neoplasms; Apoptosis
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Oncotarget
- ISSN: 1949-2553
- Volume/Número/Paginação/Ano: v. 7, n. 6, p. 6948-6959, 2016
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
CAMPOS, Paula de Melo et al. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget, v. 7, n. 6, p. 6948-6959, 2016Tradução . . Disponível em: https://doi.org/10.18632/oncotarget.6851. Acesso em: 23 abr. 2024. -
APA
Campos, P. de M., Machado Neto, J. A., Eide, C. A., Savage, S. L., Scopim-Ribeiro, R., Duarte, A. da S. S., et al. (2016). IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget, 7( 6), 6948-6959. doi:10.18632/oncotarget.6851 -
NLM
Campos P de M, Machado Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, Duarte A da SS, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Saad STO, Traina F. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms [Internet]. Oncotarget. 2016 ; 7( 6): 6948-6959.[citado 2024 abr. 23 ] Available from: https://doi.org/10.18632/oncotarget.6851 -
Vancouver
Campos P de M, Machado Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, Duarte A da SS, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Saad STO, Traina F. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms [Internet]. Oncotarget. 2016 ; 7( 6): 6948-6959.[citado 2024 abr. 23 ] Available from: https://doi.org/10.18632/oncotarget.6851 - FMNL1 is downregulated in myelodysplastic syndromes and is involved in megakaryocytic differentiation
- Increased inflammatory markers and their correlations to clinical complications in hemoglobin SC disease
- YAP1 expression in myelodysplastic syndromes and acute leukemias. [Carta]
- ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells
- Differential profile of PIP4K2A expression in hematological malignancies
- Abnormal Hedgehog pathway in myelodysplastic syndrome and its impact on patients' outcome. [Carta]
- Key endothelial cell angiogenic mechanisms are stimulated by the circulating milieu in sickle cell disease and attenuated by hydroxyurea
- Padronização da investigação laboratorial de anticorpos dirigidos contra fármacos em doadores de sangue e pacientes com anemia hemolítica imune
- Hydroxyurea therapy reduces the hypercoagulability state in a sickle cell mouse model
- Pyrimidine-5'-nucleotidase Campinas, a new mutation (p.R56G) in the NT5C3 gene associated with pyrimidine-5'-nucleotidase type I deficiency and influence of Gilbert's syndrome on clinical expression
Informações sobre o DOI: 10.18632/oncotarget.6851 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
